Therapeutic potential of PMEA as an antiviral drug
1994; Wiley; Volume: 4; Issue: 3 Linguagem: Inglês
10.1002/rmv.1980040302
ISSN1099-1654
AutoresLieve Naesens, Jan Balzarini, Erik De Clercq,
Tópico(s)Herpesvirus Infections and Treatments
ResumoReviews in Medical VirologyVolume 4, Issue 3 p. 147-159 Article Therapeutic potential of PMEA as an antiviral drug L. Naesens, Corresponding Author L. Naesens Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, BelgiumRega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, BelgiumSearch for more papers by this authorJ. Balzarini, J. Balzarini Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, BelgiumSearch for more papers by this authorE. De Clercq, E. De Clercq Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, BelgiumSearch for more papers by this author L. Naesens, Corresponding Author L. Naesens Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, BelgiumRega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, BelgiumSearch for more papers by this authorJ. Balzarini, J. Balzarini Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, BelgiumSearch for more papers by this authorE. De Clercq, E. De Clercq Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, BelgiumSearch for more papers by this author First published: September 1994 https://doi.org/10.1002/rmv.1980040302Citations: 50AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 De Clercq, E., Holý, A., Rosenberg, I., Sakuma, T., Balzarini, J. and Maudgal, P. C. (1986). A novel selective broad-spectrum anti-DNA virus agent. Nature 323, 464–467. 10.1038/323464a0 CASPubMedWeb of Science®Google Scholar 2 De Clercq, E., Sakuma, T., Baba, M. et al. (1987). Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 8, 261–272. 10.1016/S0166-3542(87)80004-9 CASPubMedWeb of Science®Google Scholar 3 De Clercq, E., (1991). Broad spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxy-alkylpurines and -pyramidines. Biochem. Pharmacol. 42, 963–972. 10.1016/0006-2952(91)90276-B CASPubMedWeb of Science®Google Scholar 4 Kim, C. U., Luh, B. Y., Misco, P. F. et al. (1989). Synthesis and biological activities of phosphonylalkylpurine derivatives. Nucleos. Nucleotid. 8, 927–931. 10.1080/07328318908054247 Web of Science®Google Scholar 5 Balzarini, J. and De Clercq, E. (1994). Acyclic purine nucleoside phosphonates as retrovirus inhibitors. In, Antiviral Chemotherapy, ed. by J. Jeffries and E. De Clercq, John Wiley & Sons, Chichester, in press. Google Scholar 6 Neyts, J., Snoeck, R., Balzarini, J. and De Clercq, E. (1991). Particular characteristics of the anti-human cytomegalovirus activity of ( S)-1-(3-hydroxy-2-phoshonylmethoxypropyl)cyt9sine (HPMPC) in vitro. Antiviral Res. 16, 41–52. 10.1016/0166-3542(91)90057-X CASPubMedWeb of Science®Google Scholar 7 Snoeck, R., Sakuma, T., De Clercq, E., Rosenberg, I. and Holý, A. (1988). (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother. 32, 1839–1844. 10.1128/AAC.32.12.1839 CASPubMedWeb of Science®Google Scholar 8 De Clercq, E. (1993). Therapeutic potential of HPMPC as an antiviral drug. Rev. Med. Virol. 3, 85–96. 10.1002/rmv.1980030205 CASWeb of Science®Google Scholar 9 Balzarini, J., Holý, A., Jindrich, J. et al. (1991). 9 - [(. RS) - 3 - Fluoro - 2 - phosphonylmethoxypropyl] derivatives of purines: a class of highly selective antiretroviral agents in vivo and in vivo. Proc. Natl Acad. Sci. USA 88, 4961–4965. 10.1073/pnas.88.11.4961 CASPubMedWeb of Science®Google Scholar 10 Balzarini, J., Holý, A., Jindrich, J. et al. (1993). Differential antiherpesvirus and antiretrovirus effects of the ( S) and ( R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of ( R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob. Agents Chemother. 37, 332–338. 10.1128/AAC.37.2.332 CASPubMedWeb of Science®Google Scholar 11 Holý, A. and Rosenberg, I. (1987). Synthesis of 9-(2-phosphonylmethoxyethyl)-adenine and related compounds. Collect. Czech. Chem. Commun. 52, 2801–2809. 10.1135/cccc19872801 CASWeb of Science®Google Scholar 12 Schwalbe, C. H., Thomson, W. and Freeman, S. (1991). Structural studies on bioactive molecules. Part 17. Crystal structure of 9-(2′-phosphonomethoxyethyl)adenine (PMEA). J. Chem. Soc. Perkin Trans. 1, 1348–1349. 10.1039/p19910001348 Web of Science®Google Scholar 13 Votruba, I., Bernaerts, R., Sakuma, T. et al. (1987). Intracellular phosphorylation of broad-spectrum anti-DNA virus agent ( S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and inhibition of viral DNA synthesis. Mol. Pharmacol. 32, 524–529. CASPubMedWeb of Science®Google Scholar 14 Bronson, J. J., Ho, H.-T., De Boeck, H. et al. (1989). Biochemical pharmacology of acyclic nucleotide analogues. Ann. N.Y. Acad. Sci. 616, 398–407. 10.1111/j.1749-6632.1990.tb17859.x PubMedWeb of Science®Google Scholar 15 Balzarini, J., Hao, Z., Herdewijn, P., Johns, D. G. and De Clercq, E. (1991). Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent antihuman immunodeficiency virus compound. Proc. Natl Acad. Sci. USA 88, 1499–1503. 10.1073/pnas.88.4.1499 CASPubMedWeb of Science®Google Scholar 16 Merta, A., Votruba, I., Rosenberg, I. et al. (1990). Inhibition of herpes simplex virus DNA polymerase by diphosphates of acyclic phosphonylmethoxyalkyl nucleotide analogues. Antiviral Res. 13, 209–218. 10.1016/0166-3542(90)90066-G CASPubMedWeb of Science®Google Scholar 17 Holý, A., Votruba, I., Merta, A. et al. (1990). Acyclic nucleotide analogues: synthesis, antiviral activity and inhibitory effects on some cellular and virus-encoded enzyme. in vitro. Antiviral Res. 13, 295–312. 10.1016/0166-3542(90)90014-X CASPubMedWeb of Science®Google Scholar 18 Votruba, I., Trávníček, M., Rosenberg, I. et al. (1990). Inhibition of avian myeloblastosis virus reverse transcriptase by diphosphates of acyclic phosphonylmethyl nucleotide analogues. Antiviral Res. 13, 287–294. 10.1016/0166-3542(90)90013-W CASPubMedWeb of Science®Google Scholar 19 Foster, S. A., Černý, J. and Cheng, Y.-C. (1991). Herpes simplex virus-specified DNA polymerase is the target for the antiviral action of 9–2 (phosphonylmethoxyethyl)adenine. J. Biol. Chem. 266, 238–244. CASPubMedWeb of Science®Google Scholar 20 Vonka, V., Anisimová, E., Černý, J., Holý, A., Rosenberg, I. and Votruba, I. (1990). Properties of a 9-(2-phosphonylmethoxyethyl)adenine (PMEA)-resistant herpes simplex virus type 1 virus mutant. Antiviral Res. 14, 117–122. 10.1016/0166-3542(90)90049-D CASPubMedWeb of Science®Google Scholar 21 Černý, J., Votruba, I., Vonka, V., Rosenberg, I., Otmar, M. and Holý, A. (1990). Phosphonylmethyl ethers of acyclic nucleoside analogues: inhibitors of HSV-1 induced ribonucleotide reductase. Antiviral Res. 13, 253–264. 10.1016/0166-3542(90)90070-N CASPubMedWeb of Science®Google Scholar 22 Šedivá, K., Ananiev, A. V., Votruba, I., Holý, A. and Rosenberg, I. (1991). Inhibition of purine nucleoside phosphorylase by phosphonylmethoxyalkyl analogues of nucleotides. Int. J. Purine Pyrimidine Res. 2, 35–39. Google Scholar 23 Veselý, J., Merta, A., Votruba, I., Rosenberg, I. and Holý, A. (1990). The cytostatic effects and mechanisms of action of antiviral acyclic adenine nucleoside analogs in L1210 mouse leukemia cells. Neoplasma 37, 105–110. PubMedWeb of Science®Google Scholar 24 Černý, J., Foster, S. A. and Cheng. Y.-C. (1992). Cell-protecting effect against herpes simplex virus-1 and cellular metabolism of 9-(2-phosphonyl-methoxyethyl)adenine in HeLa S3 cells. Mol. Pharmacol. 42, 537–544. PubMedWeb of Science®Google Scholar 25 Palú, G., Stefanelli, S., Rassu, M., Parolin, C., Balzarini, J. and De Clercq, E. (1991). Cellular uptake of phosphonylmethoxyalkylpurine derivatives. Antiviral Res. 16, 115–119. 10.1016/0166-3542(91)90063-W CASPubMedWeb of Science®Google Scholar 26 Prus, K. L., Hill, E. L. and Ellis, M. N. (1991). The transport of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) into Vero cells. Fourth International Conference Antiviral Research, New Orleans, Louisiana, USA, 21–26 April 1991. Antiviral Res. Suppl 1, 144, Abstract No. 188. Google Scholar 27 Merta, A., Votruba, I., Jindrich, J. et al. (1992). Phosphorylation of 9-(2-phosphonomethoxyethyl)-adenine and 9-(S)-(3-hydroxy-2-phosphonomethoxy-propyl) adenine by AMP (dAMP) kinase from L1210 cells. Biochem. Pharmacol. 44, 2067–2077. 10.1016/0006-2952(92)90110-5 CASPubMedWeb of Science®Google Scholar 28 Balzarini, J. and De Clercq, E. (1991). 5-Phosphoribosyl 1-pyrophosphate synthetase converts the acyclic nucleoside phosphonates 9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 9-(2-phosphonylmethoxvethyl)adenine directly to their antivirally active diphosphate derivatives. J. Biol. Chem. 266, 8686–8689. CASPubMedWeb of Science®Google Scholar 29 Balzarini, J. and De Clercq, E. (1991). Conversion of acyclic nucleoside phosphonates to their diphosphate derivatives by 5-phosphoribosyl-1-pyrophosphate (PRPP) synthetase. In, Purine and Pyrimidine Metabolism in Man VII, Part A, ed. by R. A. Harkness et al. pp. 29–32. Plenum Press, New York. 10.1007/978-1-4899-2638-8_6 Web of Science®Google Scholar 30 Pauwels, R., Balzarini, J., Schols, D. et al. (1988). Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob. Agents Chemother. 32, 1025–1030. 10.1128/AAC.32.7.1025 CASPubMedWeb of Science®Google Scholar 31 Balzarini, J., Naesens, L., Slachmuylders, J. et al. (1991). 9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replicatio. in vitro and simian immunodeficiency virus infection in rhesus monkeys. AIDS 5, 21–28. 10.1097/00002030-199101000-00003 CASPubMedWeb of Science®Google Scholar 32 Balzarini, J., Perno, C.-F., Schols, D. and De Clercq, E. (1991). Activity of acyclic nucleoside phosphonate analogues against human immunodeficiency virus in monocyte/macrophages and peripheral blood lymphocytes. Biochem. Biophys. Res. Commun. 178, 329–335. 10.1016/0006-291X(91)91818-W CASPubMedWeb of Science®Google Scholar 33 Balzarini, J., Naesens, L., Slachmuylders, J. et al. (1990). Potent anti-simian immunodeficiency virus (SIV) activity and pharmacokinetics of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in rhesus monkeys. Proceedings of the International TNO Meeting on Animal Models in AIDS, Maastricht, The Netherlands, 23–26 October 1989. In, Animal Models in AIDS, ed. by H. Schellekens and M. C. Horzinek, pp. 131–138. Elsevier, Amsterdam. Web of Science®Google Scholar 34 Egberink, H., Borst, M., Niphuis, H. et al. (1990). Suppression of feline immunodeficiency virus infectio. in vivo by 9-(2-phosphonomethoxyethyl)-adenine. Proc. Natl Acad. Sci. USA 87, 3087–3091. 10.1073/pnas.87.8.3087 CASPubMedWeb of Science®Google Scholar 35 Hartmann, K., Balzarini, J., Higgins, J., De Clercq, E. and Pedersen, N. C. (1994). In vitro activity of acyclic nucleoside phosphonate derivatives against feline immunodeficiency virus in Crandell feline kidney cells and feline peripheral blood lymphocytes. Antiviral Chem. Chemother. 5, 13–19. 10.1177/095632029400500103 CASWeb of Science®Google Scholar 36 Thormar, H., Balzarini, J., Holý, A. et al. (1993). Inhibition of visna virus replication by 2′,3′-dideoxynucleosides and acyclic nucleoside phosphonate analogs. Antimicrob. Agents Chemother. 37, 2540–2544. 10.1128/AAC.37.12.2540 CASPubMedWeb of Science®Google Scholar 37 Smith, M. S., Brian, E. L., De Clercq, E. and Pagano, J. S. (1989). Susceptibility of human immunodeficiency virus type 1 replicatio. in vitro to acyclic adenosine analogs and synergy of the analogs with 3′-azido-3′deoxythymidine. Antimicrob. Agents Chemother. 33, 1482–1486. 10.1128/AAC.33.9.1482 CASPubMedWeb of Science®Google Scholar 38 Balzarini, J., Naesens, L., Herdewijn, P. et al. (1989). Marke. in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proc. Natl Acad. Sci. USA 86, 332–336. 10.1073/pnas.86.1.332 CASPubMedWeb of Science®Google Scholar 39 Naesens, L., Balzarini, J., Rosenberg, I., Holý, A. and De Clercq, E. (1989). 9-(2-Phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP): a novel agent with anti-human immunodeficiency virus activit. in vitro and potent anti-Moloney murine sarcoma virus activity in vivo. Eur. J. Clin. Microbiol. Infect. Dis. 8, 1043–1047. 10.1007/BF01975167 CASPubMedWeb of Science®Google Scholar 40 Naesený, L., Balzarini, J., Holý, A., Rosenberg, I. and De Clercq, E. (1990). Antiretroviral efficacy of 9-(2-phosphonylmethoxyethyl)adenine and 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine in mice infected with Friend leukemia virus [Abstract]. UCLA symposia on Molecular Biology and Cellular Biology—HIV and AIDS: Pathogensis, Therapy and Vaccine Keystone, Colorado, USA, 31 March-6 April 1990. J. Cell. Biochem. 14D(Suppl), 140. Google Scholar 41 Balzarini, J., Naesens, L. and De Clercq, E. (1990). Anti-retrovirus activity of 9-(2-phosphonyl-methoxyethyl)adenine (PMEA) in vivo increases when it is less frequently administered. Int. J. Cancer 46, 337–340. 10.1002/ijc.2910460233 CASPubMedWeb of Science®Google Scholar 42 Naesens, L., Balzarini, J. and De Clercq, E. (1991). Single-dose administration of 9-(2-phosphonyl-methoxyethyl)adenine (PMEA) and 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the prophylaxis of retrovirus infectio. in vivo. Antiviral Res. 16, 53–64. 10.1016/0166-3542(91)90058-Y CASPubMedWeb of Science®Google Scholar 43 Balzarini, J., Sobis, H., Naesens, L., Vandeputte, M. and De Clercq, E. (1990). Inhibitory effects of 9-(2- phosphonylmethoxyethyl)adenine and 3′-azido-2′,3′-dideoxythymidine on tumor development in mice inoculated intracerebrally with Moloney murine sarcoma virus. Int. J. Cancer 45, 486–489. 10.1002/ijc.2910450319 CASPubMedWeb of Science®Google Scholar 44 Gangemi, J. D., Cozens, R. M., De Clercq, E., Balzarini, J. and Hochkeppel, H.-K. (1989). 9-(2-Phosphonylmethoxyethyl)adenine in the treatment of murine acquired immunodeficiency disease and opportunistic herpes simplex virus infections. Antimicrob. Agents Chemother. 33, 1864–1868. 10.1128/AAC.33.11.1864 CASPubMedWeb of Science®Google Scholar 45 De Castro, L. M., Kern, E. R., De Clercq, E. et al. (1991). Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS. Antiviral Res. 16, 101–114. 10.1016/0166-3542(91)90062-V CASPubMedWeb of Science®Google Scholar 46 Hartmann, K., Donath, A., Beer, B. et al. (1992). Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms. Vet. Immunol. Immunopathol. 35, 167–175. 10.1016/0165-2427(92)90129-E CASPubMedWeb of Science®Google Scholar 47 Hoover, E. A., Ebner, J. P., Zeidner, N. S. and Mullins, J. I. (1991). Early therapy of feline leukemia virus infection (FeLV-FAIDS) with 9-(2-phosphonylmethoxyethyl)adenine (PMEA). Antiviral Res. 16, 77–92. 10.1016/0166-3542(91)90060-5 CASPubMedWeb of Science®Google Scholar 48 Hoover, E. A., Philpott, M. S., Ebner, J. P. and Zeidner, N. S. (1992). Experimental therapy of immunodeficiency-inducing feline retroviruses with phosphonylmethoxyethyl adenine (PMEA). Fifth International Conference on Antiviral Research, Vancouver, B.C., Canada, 8–13 March 1992. Antiviral Res. Suppl. 1, 131, Abstract No. 165. Google Scholar 49 Tsai, C.-C., Follis, K. E., Sabo, A. et al. (1994). Preexposure prophylaxis with 9-(2-phosphonylmethoxyethyl)adenine (PMEA) against simian immunodeficiency virus infection in macaques. J. Infect. Dis. 169, 260–266. 10.1093/infdis/169.2.260 CASPubMedWeb of Science®Google Scholar 50 Tsai, C.-C., Follis, K. E., Grant, R. F. et al. (1993). Effect of dosing frequency on ZDV prophylaxis in macaques infected with simian immunodeficiency virus. AIDS 6, 1086–1092. CASPubMedWeb of Science®Google Scholar 51 Lundgren, B., Ljungdahl-Ståhle, E., Böttiger, D. et al. (1990). Acute infection of cynomolgus monkeys with simian immunodeficiency virus (SIVSM) as a model to evaluate antiviral compounds. Effect of 3′-azido-3′-deoxythymidine, forscarnet and 2′,3′-dideoxycytidine. Antiviral Chem. Chemother. 1, 299–306. 10.1177/095632029000100504 CASGoogle Scholar 52 Rose, W. C., Crosswell, A. R., Bronson, J. J. and Martin, J. C. (1990). In vivo antitumor activity of 9-[(2-phosphonylmethoxy)ethyl]guanine and related phosphonate nucleotide analogues. J. Natl Cancer Inst. 82, 510–512. 10.1093/jnci/82.6.510 CASWeb of Science®Google Scholar 53 Richman, D. D., Fischl, M. A., Grieco, M. H. et al. (1987). The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med. 317, 192–197. 10.1056/NEJM198707233170402 CASPubMedWeb of Science®Google Scholar 54 Del Gobbo, V., Foli, A., Balzarini, J. et al. (1991). Immunomodulatory activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), a potent anti-HIV nucleoside analogue, o. in vivo murine models. Antiviral Res. 16, 65–75. 10.1016/0166-3542(91)90059-Z CASPubMedWeb of Science®Google Scholar 55 Caliò, R., Villani, N., Balestra, E. et al. (1993). Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates. Antiviral Res. in press. Google Scholar 56 Caliò, R., Balestra, E., Perno, C.-F. et al. (1993). 9-(2-Phosphonylmethoxyethyl)adenine (PMEA) decreases the lethal effect of RNA-influenza virus in mice through an immunomodulating mechanism. Sixth International Conference on Antiviral Research Venice, Italy, 25–30 April 1993. Antiviral Res. Suppl 1, 101, Abstract No. 106. Google Scholar 57 Lin J. C., De Clercq, E. and Pagano, J. S. (1987). Novel acyclic adenosine analogs inhibit Epstein-Barr virus replication. Antimicrob. Agents Chemother. 31, 1431–1433. 10.1128/AAC.31.9.1431 CASPubMedWeb of Science®Google Scholar 58 Yokota, T., Konno, K., Chonan, E. et al. (1990). Comparative activities of several nucleoside analogs against duck hepatitis B viru. in vitro. Antimicrob. Agents Chemother. 34, 1326–1330. 10.1128/AAC.34.7.1326 CASPubMedWeb of Science®Google Scholar 59 Heijtink, R. A., De Wilde, G. A., Kruining, J. et al. (1993). Inhibitory effect of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res. 21, 141–153. 10.1016/0166-3542(93)90050-S CASPubMedWeb of Science®Google Scholar 60 Gil-Fernández, C. and De Clercq, E. (1987). Comparative efficacy of broad-spectrum antiviral agents as inhibitors of African swine fever virus replicatio. in vitro. Antiviral Res. 7, 151–160. 10.1016/0166-3542(87)90003-9 PubMedWeb of Science®Google Scholar 61 Gil-Fernández, C., Garcia-Villalón, D., De Clercq, E., Rosenberg, I. and Holý, A. (1987). Phosphonylmethoxyalkylpurines and -pyrimidines as inhibitors of African swine fever virus replicatio. in vitro. Anitviral Res. 8, 273–282. 10.1016/S0166-3542(87)80005-0 CASPubMedWeb of Science®Google Scholar 62 Snoeck, R., Andrei, G., Balzarini, J., Reymen, D. and De Clercq, E. (1994). Dipyridamole potentiates the activity of various acyclic nucleoside phosphonates against varicella-zoster virus (VZV), herpes simplex virus and human cytomegalovirus. Antiviral. Chem. Chemother. in press. Google Scholar 63 Andrei, G., Snoeck, R., Balzarini, J., Reymen, D. and De Clercq, E. (1993). Dipyridamole potentiates the activity of acyclic nucleoside phosphonates against varicella-zoster virus (VZV), herpes simplex virus (HSV) and human cytomegaloviru. in vitro. Sixth International Conference on Antiviral Research, Venice, Italy, 25–30 April 1993. Antiviral Res. Suppl 1, 109, Abstract No. 120. Google Scholar 64 Maudgal, P. C. and De Clercq, E. (1991). Efficacy of 9-(2-phosphonylmethoxyethyl)adenine in the therapy of TK+ and TK− herpes simplex virus experimental keratitis. Current Eye Res. 10, (Suppl.), 139–142. 10.3109/02713689109020370 Web of Science®Google Scholar 65 Maudgal, P. C. and De Clercq, E. (1991). Effects of phosphonylmethoxyalkyl-purine and -pyrimidine derivatives on TK+ and TK− HSV-1 keratitis in rabbits. Antiviral Res. 16, 93–100. 10.1016/0166-3542(91)90061-U CASPubMedWeb of Science®Google Scholar 66 Field, H. J. and Awan, A. R. (1990). Effective chemotherapy of equine herpesvirus 1 by phosphonyl-methoxyalkyl derivatives of adenine demonstrated in a novel murine model for the disease. Antimicrob. Agents Chemother. 34, 709–717. 10.1128/AAC.34.5.709 CASPubMedWeb of Science®Google Scholar 67 De Clercq, E., Holý, A. and Rosenberg, I. (1989). Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infection. in vivo. Antimicrob. Agents Chemother. 33, 185–191. 10.1128/AAC.33.2.185 CASPubMedWeb of Science®Google Scholar 68 Yokota, T., Mochizuki, S., Konno, K., Mori, S., Shigeta, S. and De Clercq, E. (1991). Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis. Antimicrob. Agents Chemother. 35, 394–397. 10.1128/AAC.35.2.394 CASPubMedWeb of Science®Google Scholar 69 Neyts, J., Stals, F., Bruggeman, C. and De Clercq, E. (1993). Activity of the anti-HIV agent 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine against cytomegaloviru. in vivo Eur. J. Clin. Microb. Infect. Dis. 12, 437–446. 10.1007/BF01967438 CASPubMedWeb of Science®Google Scholar 70 Naesens, L., Balzarini, J. and De Clercq, E. (1992). Pharmacokinetics in mice of the anti-retrovirus agent 9-(2-phosphonylmethoxyethyl)-adenine. Drug Metab. Disp. 20, 747–752. CASPubMedWeb of Science®Google Scholar 71 Naesens, L., Balzarini, J. and De Clercq, E. (1992). Acyclic adenine nucleoside phosphonates in plasma determined by high-performance liquid chromatography with fluorescence detection. Clin. Chem. 38, 480–485. CASPubMedWeb of Science®Google Scholar 72 Lee, J. S., Mullaney, S. Bronson, R. et al. (1991). Transplacental antiretroviral therapy with 9-(2-phosphonylmethoxyethyl)adenine is embryotoxic in transgenic mice. AIDS 4, 833–838. CASPubMedWeb of Science®Google Scholar 73 Russell, J. W., Marrero, D., Whiterock, V. J. and Klunk, L. J. (1991). Determination of 9-[(2-phosphonylmethoxy)ethyl]adenine in rat urine by high-performance liquid chromatography with fluorescence detection. J. Chromat. 572, 321–326. 10.1016/0378-4347(91)80498-2 CASPubMedWeb of Science®Google Scholar 74 Naesens, L., Neyts, J., Balzarini, J., Holý, A., Rosenberg, I. and De Clerzq, E. (1993). Efficacy of oral 9-(2-phosphonylmethoxyethyl)-2,6-diamino-purine (PMEDAP) in the treatment of retrovirus and cytomegalovirus infections in mice. J. Med. Virol. 39, 167–172. 10.1002/jmv.1890390215 CASPubMedWeb of Science®Google Scholar 75 Bischofberger, N., Prisbe, E., Arimilli, M., Cundy, K. and Lee, B. (1993). Evaluation of nucleotide prodrugs as inhibitors of viral replication. Sixth International Conference on Antiviral Research, Venice, Italy, 25–30 April 1993. Antiviral Res. Suppl 1, 142, Abstract No. 185. Google Scholar 76 Srinivas, R. V., Robbins, B. L., Connelly, M. C., Gong, Y.-F., Bischofberger, N. and Fridland, A. (1993). Metabolism an. in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phoshonates. Antimicrob. Agents Chemother. 37, 2247–2250. 10.1128/AAC.37.10.2247 CASPubMedWeb of Science®Google Scholar 77 Starrett, J. E., Tortolani, D. R., Hitchcock, M. J. M., Martin, J. C. and Mansuri, M. M. (1992). Synthesis an. in vitro evaluation of a phosphonate prodrug: bis(pivaloyloxymethyl) 9-(2-phosphonylmethoxy-ethyl)adenine. Antiviral Res. 19, 267–273. 10.1016/0166-3542(92)90084-I CASPubMedWeb of Science®Google Scholar 78 Midoux, P., Negre, E., Roche, A.-C. et al. (1990). Drug targeting: anti-HSV-1 activity of mannosylated polymer-bound 9-(2-phosphonylmethoxyethyl)-adenine. Biochem. Biophys. Res. Commnun. 167, 1044–1049. 10.1016/0006-291X(90)90628-Z CASPubMedWeb of Science®Google Scholar Citing Literature Volume4, Issue3September 1994Pages 147-159 ReferencesRelatedInformation
Referência(s)